Anavex Life Sciences Corp.
AVXL
$9.42
-$0.03-0.32%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 8.26% | 1.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.34% | -3.99% | |||
| Operating Income | 3.34% | 3.99% | |||
| Income Before Tax | -3.13% | 4.37% | |||
| Income Tax Expenses | -- | -85.07% | |||
| Earnings from Continuing Operations | -4.23% | 4.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.23% | 4.86% | |||
| EBIT | 3.34% | 3.99% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -4.23% | 5.19% | |||
| Normalized Basic EPS | -3.72% | 5.59% | |||
| EPS Diluted | -4.23% | 5.19% | |||
| Normalized Diluted EPS | -3.72% | 5.59% | |||
| Average Basic Shares Outstanding | 0.01% | 0.31% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||